Type Whole antibody Target Beta-amyloid (Aβ40/42) Legal status Investigational Molar mass 146.3 million g/mol | Source Human ATC code none CAS Number 1043556-46-2 | |
Mechanism of amyloid removal in patients with alzheimer disease treated with gantenerumab part 1
Gantenerumab is a monoclonal antibody for the treatment of Alzheimer's disease. A phase I clinical trial has been conducted in 2006/07.
Contents
- Mechanism of amyloid removal in patients with alzheimer disease treated with gantenerumab part 1
- Mechanism of amyloid removal in patients with alzheimer disease treated with gantenerumab part 3
- References
Gantenerumab is currently being evaluated in a prodromal Alzheimer's disease population in the Scarlet Road study, a global phase II study of approximately 360 subjects in 100 centers in 15 countries.
One clinical study was stopped on December 19, 2014 after disappointing results.
As of late 2014, Phase III clinical trials are ongoing.
Mechanism of amyloid removal in patients with alzheimer disease treated with gantenerumab part 3
References
Gantenerumab Wikipedia(Text) CC BY-SA